Potent Antifungal and Antiparasitic Solutions

Introduction

Fungal and parasitic infections are a growing global health concern, with many existing treatments proving inadequate due to drug resistance. These infections affect millions worldwide, leading to severe health complications, prolonged hospital stays, and in some cases, death. Our patented indoloquinoline derivatives offer a promising new class of antifungal and antiparasitic compounds, designed to overcome resistance and provide more effective treatments. These compounds represent a critical breakthrough for pharmaceutical companies aiming to develop powerful, next-generation therapies to combat these persistent infections.

The Urgent Need for New Antifungal and Antiparasitic Therapies

Fungal infections, such as candidiasis and aspergillosis, and parasitic diseases like malaria, continue to pose a significant health burden. In many cases, existing antifungal and antiparasitic treatments are becoming less effective due to the rise of drug-resistant strains. This resistance leaves healthcare providers with limited options, increasing the severity and duration of infections. The healthcare and pharmaceutical industries are in urgent need of innovative solutions to fill the growing gaps in treatment and to address both common and rare infections.

Developing new therapies that can efficiently target resistant pathogens without causing harmful side effects is a top priority. Companies that focus on these solutions will be at the forefront of addressing one of the most pressing global health challenges.

Why Choose Antifungal and Antiparasitic Solutions?

Our patented indoloquinoline derivatives offer a powerful and targeted approach to combating fungal and parasitic infections. These compounds are designed to disrupt key biological processes in the pathogens, effectively halting their growth and spread. Their unique molecular structure provides an edge in overcoming resistance, offering a promising solution where traditional treatments have failed.

This technology is highly adaptable, allowing it to be developed into a range of pharmaceutical products that can address diverse fungal and parasitic infections. From acute infections to chronic diseases, these compounds provide a new frontier in infectious disease treatment.

Key Benefits

Overcomes Drug Resistance: Targets fungal and parasitic infections resistant to current therapies.
Broad-Spectrum: Effective against multiple types of fungal and parasitic infections.
Next-Gen Therapy: Supports the development of advanced, targeted pharmaceutical treatments.
Global Health Impact: Provides critical treatment options for infections that affect millions.

Combat Infections with Antifungal and Antiparasitic Solutions

Licensing these indoloquinoline-based compounds offers pharmaceutical companies the opportunity to lead the charge in developing effective treatments for drug-resistant fungal and parasitic infections. With these powerful compounds, healthcare providers can offer better outcomes for patients facing difficult-to-treat infections.

Please see terms and conditions

Abstract
Claims

An indoloquinoline wherein the quarternary N-5 atom is a straight C(1-5) chain, a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring; the 10 position is N—R₁₀, O, S, S═O, CH₂, or C═O, where R₁₀is a branched C(1-5) chain, a heteroatom chain, a straight chain substituted terminally by a cycloalkyl or aromatic ring, a branched chain substituted terminally by a cycloalkyl or aromatic ring, a heteroatom chain substituted terminally by a cycloalkyl or aromatic ring. In one embodiment the quarternary N-5 atom is —CH₃and the 10 position is N—(CH₂)₅-Ph.

The invention claimed is:

1. A compound having the formula:

wherein:

R is, -halogen, —CF₃, —O—R₁, —S—R₁, —S—R₁O, —S—R₁O₂, —CN, —NO₂, or —NR₁R₂, wherein R₁and R₂are the same or different and are alkyl or hydrocarbylaryl;

n is the position of substitution of R;

Q is Z or NH; and

Z is N—R₁₀, O, S, S═O, CH₂, or C═O with the proviso that where Z is NH, N—CH₃, S or O, and R_nis H, R₅may not be CH₃; and

R₅and R₁₀are the same or different and are each independently a straight or branched C_1-5chain substituted terminally by a cycloalkyl or aromatic ring.

2. The compound of claim 1, wherein the halogen is Cl, Br, F, or I.

3. The compound of claim 1, wherein R₅is —CH₃; and Z is N—(CH₂)₅-Ph.

4. The compound of claim 1, wherein said compound is a quaternary salt.

5. The compound of claim 4, wherein said quaternary salt has the formula:

wherein: X is an anion, wherein X is I or tosylate.

6. A pharmaceutical composition comprising a pharmacologically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6 comprising a pharmacologically antimycobacterial, antimalarial, or antifungal effective amount of the compound and a pharmaceutically acceptable carrier.

8. A method of treating a mammal in need of antimycobacterial, antimalarial, or antifungal-therapy comprising administering thereto a pharmacologically effective amount of a compound of claim 1.

9. An article of manufacture comprising packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent is effective for the treatment of a subject suffering from one or more of conditions of: a fungal infection, a mycobacterial infection, or malaria, and wherein said packaging material comprises a label which indicates that said pharmaceutical agent can be used for ameliorating the symptoms associated with said condition and wherein said pharmaceutical agent is a compound of claim 1.

Title

Antifungal and antiparasitic indoloquinoline derivatives

Inventor(s)

Seth Y. Ablordeppey

Assignee(s)

Florida Agricultural and Mechanical University FAMU

Patent #

8703798

Patent Date

April 22, 2014